KI67 and DLX2 predict increased risk of metastasis formation in prostate cancer–a targeted molecular approach

[1] Antonarakis ES(2012)An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy Cancer 118 6063-6071

[2] Keizman D(2008)An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors Nat Genet 40 499-507

[3] Zhang Z(2009)Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study Br J Cancer 100 888-893

[4] Gurel B(2004)X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization Clin Cancer Res 10 7252-7259

[5] Lotan TL(2005)cAMP induced modifications of HOX D gene expression in prostate cells allow the identification of a chromosomal area involved J Cell Physiol 205 202-210

[6] Hicks JL(2012) with neuroendocrine differentiation of human advanced prostate cancers Prostate 72 713-720

[7] Fedor HL(2012)Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases Br J Cancer 106 1095-1099

[8] Carducci MA(2011)Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort Lancet Oncol 12 245-255

[9] De Marzo AM(2005)Prognostic value of an RNA expression signature derived from cell cycle proliferation genes for recurrence and death from prostate cancer: A retrospective study in two cohorts Am J Surg Pathol 29 1228-1242

[10] Eisenberger MA(2013)The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma Br J Cancer 108 271-277

[1] Antonarakis ES(2012)An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy Cancer 118 6063-6071

[2] Keizman D(2008)An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors Nat Genet 40 499-507

[3] Zhang Z(2009)Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study Br J Cancer 100 888-893

[4] Gurel B(2004)X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization Clin Cancer Res 10 7252-7259

[5] Lotan TL(2005)cAMP induced modifications of HOX D gene expression in prostate cells allow the identification of a chromosomal area involved J Cell Physiol 205 202-210

[6] Hicks JL(2012) with neuroendocrine differentiation of human advanced prostate cancers Prostate 72 713-720

[7] Fedor HL(2012)Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases Br J Cancer 106 1095-1099

[8] Carducci MA(2011)Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort Lancet Oncol 12 245-255

[9] De Marzo AM(2005)Prognostic value of an RNA expression signature derived from cell cycle proliferation genes for recurrence and death from prostate cancer: A retrospective study in two cohorts Am J Surg Pathol 29 1228-1242

[10] Eisenberger MA(2013)The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma Br J Cancer 108 271-277